Li Anji, Sun Shuai, Song Tao, Li Xi, Cheng Wen, Yao Ruipin, Zhang Danying, Cai Zailong, Zhang Jie, Zhai Dongxia, Yu Chaoqin
Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People's Republic of China.
Department of Gynecology of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, People's Republic of China,
Onco Targets Ther. 2018 Jun 27;11:3705-3711. doi: 10.2147/OTT.S162985. eCollection 2018.
Ovarian adenosquamous carcinoma is an extremely rare type of ovarian histology. Platinum-refractory disease is also uncommon, but can be fatal because of the lack of available treatment options. To date, there is no study or case report on platinum-refractory ovarian adenosquamous carcinoma or its relevant treatment.
Herein, we report the case of a 38-year-old Chinese woman with platinum-refractory advanced ovarian adenosquamous carcinoma who received clinical benefit from poly adenosine diphosphate ([ADP] ribose) polymerase and programmed death-1 inhibitors after failure of prior multiline chemotherapies and antiangiogenic agents. The targeted therapy and immunotherapy-controlled disease deterioration and improved performance status. Thus far, the patient has survived longer than 15 months, and she is taking nivolumab as maintenance treatment.
Targeted therapy and immunotherapy may be options for rare categories of ovarian cancer, but this warrants more clinical evidence of efficacy and toxicity.
卵巢腺鳞癌是一种极为罕见的卵巢组织学类型。铂类难治性疾病也不常见，但由于缺乏有效的治疗选择可能会致命。迄今为止，尚无关于铂类难治性卵巢腺鳞癌或其相关治疗的研究或病例报告。
在此，我们报告一例38岁中国女性铂类难治性晚期卵巢腺鳞癌病例，该患者在先前多线化疗和抗血管生成药物治疗失败后，接受聚腺苷二磷酸（[ADP]核糖）聚合酶和程序性死亡-1抑制剂治疗并获得临床获益。靶向治疗和免疫治疗控制了疾病进展并改善了身体状况。迄今为止，该患者已存活超过15个月，目前正在接受纳武单抗维持治疗。
靶向治疗和免疫治疗可能是罕见类型卵巢癌的治疗选择，但这需要更多关于疗效和毒性的临床证据。
